On Oct 31, major Wall Street analysts update their ratings for $Stryker Corp (SYK.US)$, with price targets ranging from $370 to $420.
J.P. Morgan analyst Robbie Marcus maintains with a buy rating, and adjusts the target price from $325 to $420.
BofA Securities analyst Travis Steed maintains with a buy rating, and sets the target price at $400.
Citi analyst Joanne Wuensch maintains with a buy rating, and sets the target price at $411.
Barclays analyst Matt Miksic maintains with a buy rating, and adjusts the target price from $402 to $418.
UBS analyst Danielle Antalffy maintains with a hold rating, and adjusts the target price from $351 to $370.
Furthermore, according to the comprehensive report, the opinions of $Stryker Corp (SYK.US)$'s main analysts recently are as follows:
The company delivered a strong performance, underscored by an 11.5% organic growth and double-digit expansion across the majority of its significant segments, coupled with better-than-expected operating margins.
Stryker's Q3 outcomes surpassed expectations, demonstrating robust double-digit growth in both revenue and earnings, coupled with an increase in operating margins.
Stryker's recent financial performance exceeded expectations at the top line. Looking ahead to 2025, the company's growth is anticipated to be fueled by a series of new product introductions, the positive impact of mergers and acquisitions with an estimated seven deals poised to contribute to growth, and the ongoing increase in the utilization of Mako, particularly with two new indications. However, a neutral stance is being maintained until there is a clear indication of sales and EPS outperformance compared to the consensus.
Stryker demonstrated robust and varied performance in the third quarter, with revenues reaching $5.494B, surpassing expectations. While the company's implied organic growth rate of 7.5% - 8.0% is below its historical averages for a seasonally strong quarter, it still anticipates healthy procedural dynamics, positive pricing trends, and product development initiatives to maintain its superior growth trajectory.
The recent quarter showed a strong performance for Stryker, with global organic growth picking up pace to hit double digits, a notable positive shift in orthopedic pricing for the first time in ten years, and earnings per share expanding at or above the mid-teen range.
Here are the latest investment ratings and price targets for $Stryker Corp (SYK.US)$ from 15 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月31日，多家华尔街大行更新了$史赛克 (SYK.US)$的评级，目标价介于370美元至420美元。
摩根大通分析师Robbie Marcus维持买入评级，并将目标价从325美元上调至420美元。
美银证券分析师Travis Steed维持买入评级，目标价400美元。
花旗分析师Joanne Wuensch维持买入评级，目标价411美元。
巴克莱银行分析师Matt Miksic维持买入评级，并将目标价从402美元上调至418美元。
瑞士银行分析师Danielle Antalffy维持持有评级，并将目标价从351美元上调至370美元。
此外，综合报道，$史赛克 (SYK.US)$近期主要分析师观点如下：
公司表现强劲，有机增长率达到11.5%，在大部分显著业务板块均实现两位数增长，加上超出预期的运营利润率提升。
赛乐公司的第三季度业绩超出预期，展现出强劲的双位数营收和盈利增长，同时运营利润率有所增加。
赛乐公司最近的财务表现超出预期的顶线。展望到2025年，公司的增长有望受到一系列新产品推出、与预计将有七项交易为增长做出贡献的合并收购的积极影响，以及对Mako利用的持续增加，特别是有两项新适应症。然而，当前保持中立立场，直到有明确的迹象显示销售和每股收益表现优于共识。
赛乐公司第三季度表现强劲而多样化，营收达到54.94亿美元，超出预期。尽管公司暗示的有机增长率为7.5% - 8.0%，低于历史上季节性强的季度平均水平，但仍预计健康的程序动态、积极的价格趋势和产品开发举措将维持其优越的增长轨迹。
最近一个季度对赛乐公司来说表现强劲，全球有机增长率加速，达到两位数，骨科产品价格出现十年来值得注意的积极变化，每股收益扩大至或超过中青少年范围。
以下为今日15位分析师对$史赛克 (SYK.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
